Our developments

What is Liquid biopsy?


Liquid biopsy is a non-invasive diagnostic technique that allows the detection of tumor material from a body fluid sample.  This technique will serve to improve the diagnosis, prognosis and follow-up of any tumor, and estimate its probabilities of metastasis, the event with the greatest clinical impact today in oncology. Liquid biopsy is considered the technology with the greatest potential for impact on the oncology diagnostic market.


Nasasbiotech is developing a new approach in the field of liquid biopsy from the analysis of circulating tumor cells (CTC), the circulating tumor DNA (ctDNA) and the extracellular vesicles (EVs). These vesicles are one of the main mediators of cell-cell communication and they are revolutionizing the field of liquid biopsy as carriers of nucleic acids (DNA, RNA, miRNA…), proteins and lipids that reflect the state of the diseases.


The competitive advantage of extracellular vesicles as biomarkers is based mainly on their greater stability and integrity and on their relative abundance associated with the process of tumor progression.

What is ExoGAG?

ExoGAG is a patented extracellular vesicles purification method that allows almost all EVs to be isolated from a liquid biopsy sample. After isolation, it allows the analysis of proteins (ELISA , protein arrays,) or genetic material (DNA, RNA or miRNA) contained in the EVs, by gPCR, ddPCR, BEAMing, sequencing, etc, which makes it an ideal product for the search of biomarkers.

1st Step

Mix the sample and ExoGAG precipitation reagent and incubate for 5 min at 4ºC.

2nd Step

Centrifuge the sample at 16.000g, 15 min and 4ºC.

3rd Step

Remove the supernatant and resuspend the EVs in the appropriate buffer, depending on the subsequent technique.